Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, November 29 '25)

Image
By G.M.

 


    BMC Pediatr

  1. KIM S, Talluri R, Yu A, Evans M, et al
    The effect of the COVID-19 pandemic on racial disparities in suicide and homicide by firearm rates in Missouri.
    BMC Pediatr. 2025;25:953.
    PubMed         Abstract available


    Epidemiol Infect

  2. CHUA H, Tsang TKL, Lee SL, Chan ELY, et al
    Waning in influenza vaccine effectiveness against influenza A(H1N1)pdm09-associated hospitalization in children in 2012/13.
    Epidemiol Infect. 2025 Nov 24:1-25. doi: 10.1017/S0950268825100770.
    PubMed        


    J Infect Dis

  3. ZHANG X, Lam SJ, Chen LL, Fong CH, et al
    Avian influenza virus A(H5N1) genotype D1.1 is better adapted to human nasal and airway organoids than genotype B3.13.
    J Infect Dis. 2025 Nov 24:jiaf598. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  4. MITCHELL JK, Mastrodomenico V, Hartnett J, Heelan WJ, et al
    A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement.
    J Virol. 2025 Oct 8:e0099125. doi: 10.1128/jvi.00991.
    PubMed         Abstract available

  5. WANG W, Du P, Zhao Y, Liang Y, et al
    Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.
    J Virol. 2025 Oct 10:e0031525. doi: 10.1128/jvi.00315.
    PubMed         Abstract available

  6. DADONAITE B, Harari S, Larsen BB, Kampman L, et al
    Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants.
    J Virol. 2025 Oct 13:e0142325. doi: 10.1128/jvi.01423.
    PubMed         Abstract available

  7. DING S, Yang D, Ullah I, Niu L, et al
    Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.
    J Virol. 2025 Oct 13:e0103425. doi: 10.1128/jvi.01034.
    PubMed         Abstract available

  8. DETTE A, Moers F, Mayr T, Stillfried Sv, et al
    Differential expression of viral entry protein neuropilin 1 (NRP1) and neuropilin 2 (NRP2) in fatal COVID-19.
    J Virol. 2025 Oct 29:e0138425. doi: 10.1128/jvi.01384.
    PubMed         Abstract available

  9. JOHNSON KEE, Stein S, Boateng RA, Jain S, et al
    Tissue tropism and functional adaptation of the SARS-CoV-2 spike protein in a fatal case of COVID-19.
    J Virol. 2025 Oct 31:e0085725. doi: 10.1128/jvi.00857.
    PubMed         Abstract available

  10. WANG C, Shuai L, Zhong G, Wen Z, et al
    Transmission of SARS-CoV-2 between ferrets in presence of pre-existing immunity.
    J Virol. 2025 Nov 4:e0156625. doi: 10.1128/jvi.01566.
    PubMed         Abstract available

  11. IRELAND J, Myers D, Huang C, Allen C, et al
    Vaccination protects against COVID-associated pulmonary fibrin deposition.
    J Virol. 2025 Nov 6:e0063325. doi: 10.1128/jvi.00633.
    PubMed         Abstract available

  12. POWERS JM, Leist SR, Suryadevara N, Zost SJ, et al
    Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice.
    J Virol. 2025 Nov 6:e0140625. doi: 10.1128/jvi.01406.
    PubMed         Abstract available

  13. ZHAO M, Zhang Y, Liang Y, Lei F, et al
    SARS-CoV-2 polyprotein expression and the induction of double-membrane vesicles.
    J Virol. 2025 Nov 6:e0138525. doi: 10.1128/jvi.01385.
    PubMed         Abstract available

  14. YU W, He X, Zhao J, Dou Y, et al
    Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model.
    J Virol. 2025 Nov 24:e0132725. doi: 10.1128/jvi.01327.
    PubMed         Abstract available

  15. SHEN W, Xu J, Chen Z, Wei Y, et al
    Broad-spectrum inhibition of influenza A virus replication by blocking the nuclear export of viral ribonucleoprotein complexes.
    J Virol. 2025 Nov 25:e0147825. doi: 10.1128/jvi.01478.
    PubMed         Abstract available

  16. SAUL S, Dahal B, Luongo C, Liu X, et al
    Intranasal bovine/human parainfluenza virus 3 vaccine candidates expressing human metapneumovirus wild-type or pre-fusion F protein elicit protective immunity against human metapneumovirus in hamsters.
    J Virol. 2025 Nov 25:e0114525. doi: 10.1128/jvi.01145.
    PubMed         Abstract available

  17. HUANG J, Xu S, Liu J, Wang Q, et al
    The viral proteins of influenza A virus competitively bind to TRIM31 with MAVS to fine-tune the antiviral innate immunity.
    J Virol. 2025 Nov 26:e0189325. doi: 10.1128/jvi.01893.
    PubMed         Abstract available


    PLoS Comput Biol

  18. GOZZI N, Chinazzi M, Davis JT, Gioannini C, et al
    Epydemix: An open-source Python package for epidemic modeling with integrated approximate Bayesian calibration.
    PLoS Comput Biol. 2025;21:e1013735.
    PubMed         Abstract available

  19. TANG J, Rumack A, Wilder B, Rosenfeld R, et al
    Real-time forecasting of data revisions in epidemic surveillance streams.
    PLoS Comput Biol. 2025;21:e1013709.
    PubMed         Abstract available

  20. WICHMANN RM, Robiati Bigoto MA, Chiavegatto Filho ADP
    Federated learning for COVID-19 mortality prediction in a multicentric sample of 21 hospitals.
    PLoS Comput Biol. 2025;21:e1013695.
    PubMed         Abstract available


    PLoS One

  21. FISHER SS, Lindaas A, Muthuri SG, Lloyd PC, et al
    Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
    PLoS One. 2025;20:e0333704.
    PubMed         Abstract available

  22. GUAN W, Liu M, Rong S, Liu T, et al
    Analysis of arrhythmia and its risk factors in patients with COVID-19.
    PLoS One. 2025;20:e0336370.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  23. OKADA T, Isacchini G, Yu Q, Hallatschek O, et al
    Uncovering heterogeneous intercommunity disease transmission from neutral allele frequency time series.
    Proc Natl Acad Sci U S A. 2025;122:e2500663122.
    PubMed         Abstract available

  24. CAI J, Wu Y, Liu H, Deng Z, et al
    China's post-zero-COVID Omicron wave: A Bayesian analysis.
    Proc Natl Acad Sci U S A. 2025;122:e2514157122.
    PubMed         Abstract available

  25. CAPUCETTI A, Falivene J, Pizzichetti C, Latino I, et al
    Tattoo ink induces inflammation in the draining lymph node and alters the immune response to vaccination.
    Proc Natl Acad Sci U S A. 2025;122:e2510392122.
    PubMed         Abstract available


    Vaccine

  26. HUANG F, Deng Z, Huang Y, Lv Q, et al
    COVID-19 as a catalyst? Uptake and drivers of seasonal influenza and pneumococcal vaccination among older adults in post-pandemic Shenzhen, China.
    Vaccine. 2025;69:128013.
    PubMed         Abstract available

  27. CHILVER M, Ahsani Z, Sullivan SG, Edwards J, et al
    Evaluating the role of self-collected home swab data in enhancing influenza vaccine effectiveness estimates in general practice.
    Vaccine. 2025;69:127994.
    PubMed         Abstract available

  28. CARACO Y, Madar-Balakirski N, Ben-Ami E, Zeltser D, et al
    Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults.
    Vaccine. 2025;67:127837.
    PubMed         Abstract available

  29. OIKAWA K, Murakami M, Ochi S, Yamagata M, et al
    Contributing factors to reversed willingness to vaccinate after the COVID-19 pandemic: Insights from a national panel survey.
    Vaccine. 2025;67:127869.
    PubMed         Abstract available

  30. MERCADANTE E, Minssen T, Shadlen KC, van Zimmeren E, et al
    A global landscape of patenting activity in COVID-19 vaccines.
    Vaccine. 2025;67:127866.
    PubMed         Abstract available

  31. MALTEZOU HC, Drositis I, Sourri F, Tseroni M, et al
    Understanding the attitudes of unvaccinated COVID-19 patients hospitalized in Greece toward the 2024-2025 booster COVID-19 vaccine.
    Vaccine. 2025;67:127829.
    PubMed         Abstract available

  32. EAGAN RL, Claessens T, Hendrickx G, Larson HJ, et al
    The state of vaccine confidence among the general public in Eastern Europe and Central Asia.
    Vaccine. 2025;67:127849.
    PubMed         Abstract available

  33. PORTER A, Cooper S, King A, Presti C, et al
    Regional voices, different choices: Parents' and caregivers' HPV vaccine attitudes in the northeast and Southeast United States.
    Vaccine. 2025;67:127864.
    PubMed         Abstract available

  34. ASTURIAS EJ, Chen LH, Shaw AC, Moser CA, et al
    Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes.
    Vaccine. 2025;67:127876.
    PubMed         Abstract available

  35. ABDUL AZIZ N, Kirsebom FCM, Allen A, Andrews N, et al
    Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England.
    Vaccine. 2025;67:127870.
    PubMed         Abstract available

  36. ULRICH AK, Bigalke L, Arpey M, Redepenning S, et al
    Funding the priorities of the influenza vaccines research and development roadmap: an evaluation of global investment.
    Vaccine. 2025;69:127967.
    PubMed         Abstract available


    Virus Res

  37. GABBAY U, Carmi D
    The Paradox of Rapid and Synchronized Propagation of Seasonal Influenza 'A' Outbreaks in Contrast with COVID-19: a Testable Hypothesis.
    Virus Res. 2025 Nov 26:199670. doi: 10.1016/j.virusres.2025.199670.
    PubMed         Abstract available

  38. LI X, Xiao M
    Retrospective study on the correlation between biochemical and blood routine indexes and prognosis in elderly patients with influenza A (H1N1).
    Virus Res. 2025;362:199668.
    PubMed         Abstract available

  39. HU J, Liu M, Qin B, Shen B, et al
    D-dimer drives immune dysregulation in COVID-19 via chemokine modulation and inflammatory signaling.
    Virus Res. 2025;361:199641.
    PubMed         Abstract available

  40. VOKO Z, Turi G, Oroszi B, Belicza E, et al
    Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic.
    Virus Res. 2025;361:199633.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »